PEGASYS® (Peginterferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 03 Feb 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 20 May 2009 Planned number of patients changed from 150 to 250 as reported by ClinicalTrials.gov.